SCYX-7158 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 2 |
65. Primary immunodeficiency
Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03087955 (ClinicalTrials.gov) | October 11, 2016 | 7/3/2017 | Prospective Study on Efficacy and Safety of Acoziborole (SCYX-7158) in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense | Efficacy and Safety Study of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Gambiense: a Multicentre, Open-label, Prospective Study | Trypanosomiasis, African;Gambiense Trypanosomiasis;Sleeping Sickness | Drug: Acoziborole (SCYX-7158) | Drugs for Neglected Diseases | NULL | Completed | 15 Years | N/A | All | 260 | Phase 2/Phase 3 | Congo, The Democratic Republic of the;Guinea |
| 2 | NCT01533961 (ClinicalTrials.gov) | February 2012 | 13/2/2012 | Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158 | Randomized, Double-blind, Placebo-controlled Sequential Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCYX-7158 After Single Oral Ascending Doses in Healthy Male Volunteers | Trypanosomiasis;Trypanosomiasis, African;Protozoan Infections;Parasitic Diseases | Drug: SCYX-7158;Drug: Placebo | Drugs for Neglected Diseases | NULL | Completed | 18 Years | 45 Years | Male | 136 | Phase 1 | France |